Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 91 | 2024 | 13500 | 4.500 |
Why?
|
Pneumonectomy | 45 | 2024 | 1148 | 3.620 |
Why?
|
Thoracic Surgical Procedures | 15 | 2023 | 348 | 3.380 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 42 | 2024 | 5394 | 2.540 |
Why?
|
Esophageal Neoplasms | 18 | 2023 | 1663 | 1.660 |
Why?
|
Solitary Pulmonary Nodule | 7 | 2023 | 281 | 1.600 |
Why?
|
Esophagectomy | 12 | 2023 | 478 | 1.530 |
Why?
|
Pleural Neoplasms | 18 | 2023 | 584 | 1.430 |
Why?
|
Mesothelioma | 20 | 2023 | 774 | 1.380 |
Why?
|
Early Detection of Cancer | 13 | 2024 | 3238 | 1.290 |
Why?
|
Thoracic Surgery, Video-Assisted | 12 | 2022 | 297 | 1.220 |
Why?
|
Thoracotomy | 8 | 2022 | 374 | 1.010 |
Why?
|
Neoplasm Staging | 49 | 2024 | 11221 | 0.940 |
Why?
|
Adenocarcinoma | 13 | 2023 | 6372 | 0.870 |
Why?
|
Manubrium | 1 | 2022 | 8 | 0.800 |
Why?
|
Tomography, X-Ray Computed | 21 | 2023 | 20757 | 0.790 |
Why?
|
Neoadjuvant Therapy | 16 | 2023 | 2903 | 0.780 |
Why?
|
Respiratory Paralysis | 1 | 2021 | 32 | 0.770 |
Why?
|
Carcinoma, Large Cell | 2 | 2021 | 114 | 0.760 |
Why?
|
Thoracoscopy | 8 | 2013 | 186 | 0.760 |
Why?
|
Bronchial Fistula | 4 | 2023 | 83 | 0.750 |
Why?
|
Postoperative Complications | 30 | 2024 | 15831 | 0.740 |
Why?
|
Lymphatic Metastasis | 11 | 2023 | 2908 | 0.740 |
Why?
|
Geriatric Assessment | 9 | 2023 | 1422 | 0.680 |
Why?
|
Diaphragm | 1 | 2021 | 357 | 0.680 |
Why?
|
Preoperative Care | 8 | 2020 | 2255 | 0.650 |
Why?
|
Thoracic Surgery | 7 | 2023 | 727 | 0.650 |
Why?
|
Pulmonary Surgical Procedures | 3 | 2014 | 33 | 0.630 |
Why?
|
Sutures | 2 | 2021 | 282 | 0.620 |
Why?
|
Mass Screening | 8 | 2020 | 5458 | 0.580 |
Why?
|
Bronchi | 1 | 2020 | 848 | 0.540 |
Why?
|
Paraneoplastic Syndromes | 1 | 2018 | 154 | 0.530 |
Why?
|
Aged | 102 | 2024 | 171453 | 0.520 |
Why?
|
Prostheses and Implants | 1 | 2022 | 1276 | 0.480 |
Why?
|
Humans | 184 | 2024 | 767998 | 0.480 |
Why?
|
Thymoma | 3 | 2022 | 186 | 0.460 |
Why?
|
Neuromyelitis Optica | 1 | 2018 | 266 | 0.450 |
Why?
|
Robotics | 2 | 2021 | 814 | 0.440 |
Why?
|
Lung Transplantation | 5 | 2009 | 1310 | 0.430 |
Why?
|
Thymus Neoplasms | 3 | 2022 | 272 | 0.420 |
Why?
|
Exercise Therapy | 1 | 2020 | 939 | 0.420 |
Why?
|
Lymphoma | 1 | 2021 | 1897 | 0.400 |
Why?
|
Thoracic Neoplasms | 3 | 2017 | 269 | 0.390 |
Why?
|
Tobacco Use Cessation | 1 | 2013 | 100 | 0.390 |
Why?
|
Esophagus | 2 | 2016 | 1042 | 0.390 |
Why?
|
Suture Techniques | 1 | 2016 | 775 | 0.370 |
Why?
|
Length of Stay | 13 | 2024 | 6495 | 0.370 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 613 | 0.360 |
Why?
|
Lymph Nodes | 7 | 2023 | 3472 | 0.360 |
Why?
|
Pericardium | 2 | 2008 | 681 | 0.350 |
Why?
|
Survival Rate | 26 | 2021 | 12827 | 0.350 |
Why?
|
Laparoscopy | 3 | 2016 | 2042 | 0.340 |
Why?
|
Pericardiectomy | 2 | 2008 | 45 | 0.330 |
Why?
|
Arterio-Arterial Fistula | 1 | 2009 | 20 | 0.330 |
Why?
|
Bronchial Arteries | 1 | 2009 | 23 | 0.330 |
Why?
|
Prognosis | 25 | 2023 | 29984 | 0.330 |
Why?
|
Cisplatin | 7 | 2018 | 1658 | 0.320 |
Why?
|
Retrospective Studies | 45 | 2024 | 81748 | 0.310 |
Why?
|
Spinal Neoplasms | 1 | 2015 | 715 | 0.310 |
Why?
|
Age Factors | 15 | 2024 | 18405 | 0.310 |
Why?
|
Esophageal Stenosis | 3 | 2023 | 196 | 0.310 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2540 | 0.310 |
Why?
|
Thoracic Diseases | 1 | 2009 | 99 | 0.310 |
Why?
|
Reperfusion | 1 | 2009 | 266 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2021 | 3553 | 0.290 |
Why?
|
Smoking | 5 | 2023 | 9087 | 0.290 |
Why?
|
Pericardial Effusion | 2 | 2008 | 246 | 0.290 |
Why?
|
Chest Tubes | 2 | 2021 | 153 | 0.290 |
Why?
|
Neoplasms | 11 | 2023 | 22369 | 0.280 |
Why?
|
Collagen Type IV | 2 | 2005 | 125 | 0.280 |
Why?
|
Leiomyosarcoma | 1 | 2011 | 426 | 0.280 |
Why?
|
Middle Aged | 74 | 2024 | 223422 | 0.280 |
Why?
|
Risk Assessment | 16 | 2024 | 24317 | 0.280 |
Why?
|
Radiography, Thoracic | 2 | 2012 | 1321 | 0.280 |
Why?
|
Esophageal Perforation | 1 | 2007 | 65 | 0.270 |
Why?
|
Male | 94 | 2024 | 364638 | 0.270 |
Why?
|
Intubation | 1 | 2007 | 140 | 0.270 |
Why?
|
Quality of Life | 7 | 2023 | 13489 | 0.270 |
Why?
|
Aged, 80 and over | 38 | 2022 | 59600 | 0.270 |
Why?
|
Radiation Dosage | 4 | 2020 | 1967 | 0.260 |
Why?
|
Frail Elderly | 5 | 2023 | 781 | 0.260 |
Why?
|
Combined Modality Therapy | 16 | 2020 | 8536 | 0.260 |
Why?
|
Orthopedic Procedures | 1 | 2015 | 1279 | 0.250 |
Why?
|
Quality Improvement | 1 | 2020 | 3856 | 0.240 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7439 | 0.240 |
Why?
|
Female | 89 | 2024 | 397102 | 0.240 |
Why?
|
Lymph Node Excision | 5 | 2023 | 1269 | 0.240 |
Why?
|
Risk Factors | 26 | 2024 | 74938 | 0.240 |
Why?
|
Morbidity | 3 | 2020 | 1754 | 0.230 |
Why?
|
Pleural Diseases | 3 | 2023 | 138 | 0.230 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2011 | 1788 | 0.220 |
Why?
|
Treatment Outcome | 35 | 2024 | 65360 | 0.220 |
Why?
|
Pneumothorax | 2 | 2021 | 393 | 0.220 |
Why?
|
Vascular Fistula | 1 | 2003 | 50 | 0.210 |
Why?
|
Lung | 9 | 2023 | 10096 | 0.210 |
Why?
|
Empyema | 2 | 2021 | 41 | 0.210 |
Why?
|
Hydroxamic Acids | 1 | 2006 | 483 | 0.210 |
Why?
|
Models, Anatomic | 2 | 2017 | 680 | 0.210 |
Why?
|
Reperfusion Injury | 1 | 2009 | 1041 | 0.210 |
Why?
|
Delirium | 3 | 2020 | 1698 | 0.210 |
Why?
|
Soft Tissue Neoplasms | 1 | 2011 | 1164 | 0.200 |
Why?
|
Uterine Neoplasms | 1 | 2011 | 1424 | 0.200 |
Why?
|
Incidence | 8 | 2023 | 21533 | 0.200 |
Why?
|
SEER Program | 4 | 2021 | 1444 | 0.200 |
Why?
|
Methylmethacrylate | 1 | 2022 | 39 | 0.200 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 3618 | 0.200 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2018 | 3626 | 0.200 |
Why?
|
Medical Oncology | 5 | 2023 | 2341 | 0.200 |
Why?
|
Phrenic Nerve | 1 | 2021 | 81 | 0.190 |
Why?
|
Methacrylates | 1 | 2022 | 110 | 0.190 |
Why?
|
Smoking Cessation | 3 | 2023 | 2085 | 0.190 |
Why?
|
Digestive System Surgical Procedures | 1 | 2007 | 585 | 0.190 |
Why?
|
Clinical Trials as Topic | 6 | 2012 | 8052 | 0.190 |
Why?
|
Patient Selection | 7 | 2018 | 4258 | 0.190 |
Why?
|
Fistula | 2 | 2007 | 213 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 11874 | 0.190 |
Why?
|
Chyle | 1 | 2021 | 17 | 0.190 |
Why?
|
Health Promotion | 1 | 2013 | 2210 | 0.190 |
Why?
|
Gastric Fistula | 1 | 2002 | 73 | 0.180 |
Why?
|
Thymectomy | 2 | 2022 | 200 | 0.180 |
Why?
|
Follow-Up Studies | 17 | 2020 | 39340 | 0.180 |
Why?
|
Hyperthermia, Induced | 3 | 2018 | 414 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 9412 | 0.180 |
Why?
|
Histone Deacetylases | 1 | 2005 | 717 | 0.180 |
Why?
|
Biomedical Research | 1 | 2016 | 3464 | 0.180 |
Why?
|
Truth Disclosure | 1 | 2004 | 434 | 0.180 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6973 | 0.180 |
Why?
|
Spectroscopy, Near-Infrared | 2 | 2017 | 749 | 0.170 |
Why?
|
Adult | 47 | 2023 | 223577 | 0.170 |
Why?
|
Telomerase | 1 | 2005 | 751 | 0.170 |
Why?
|
Precancerous Conditions | 2 | 2004 | 984 | 0.170 |
Why?
|
Mediastinum | 3 | 2013 | 272 | 0.170 |
Why?
|
Lung Diseases | 5 | 2007 | 1944 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5717 | 0.170 |
Why?
|
Rehabilitation | 1 | 2020 | 129 | 0.160 |
Why?
|
Disease-Free Survival | 7 | 2022 | 6843 | 0.160 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2564 | 0.160 |
Why?
|
Advisory Committees | 3 | 2012 | 797 | 0.160 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2005 | 2428 | 0.160 |
Why?
|
Gene Silencing | 1 | 2005 | 1505 | 0.160 |
Why?
|
Time Factors | 16 | 2024 | 40210 | 0.160 |
Why?
|
Survival Analysis | 12 | 2016 | 10096 | 0.150 |
Why?
|
Gastroesophageal Reflux | 2 | 2006 | 836 | 0.150 |
Why?
|
Predictive Value of Tests | 14 | 2019 | 15443 | 0.150 |
Why?
|
Transplantation, Autologous | 2 | 2022 | 2119 | 0.150 |
Why?
|
Anastomosis, Surgical | 2 | 2023 | 992 | 0.140 |
Why?
|
Radiotherapy | 3 | 2016 | 1501 | 0.140 |
Why?
|
Specialties, Surgical | 1 | 2021 | 391 | 0.140 |
Why?
|
Canada | 2 | 2012 | 2130 | 0.140 |
Why?
|
Myasthenia Gravis | 1 | 1999 | 214 | 0.140 |
Why?
|
Saphenous Vein | 1 | 1999 | 519 | 0.130 |
Why?
|
Graft Occlusion, Vascular | 1 | 1999 | 538 | 0.130 |
Why?
|
Testicular Neoplasms | 1 | 2022 | 806 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2021 | 4050 | 0.130 |
Why?
|
Competitive Behavior | 1 | 2016 | 78 | 0.130 |
Why?
|
Societies, Medical | 4 | 2020 | 3965 | 0.120 |
Why?
|
Antineoplastic Agents | 6 | 2018 | 13658 | 0.120 |
Why?
|
Biopsy | 5 | 2007 | 6786 | 0.120 |
Why?
|
Intraoperative Care | 4 | 2015 | 768 | 0.120 |
Why?
|
Clavicle | 1 | 1997 | 224 | 0.120 |
Why?
|
Focal Adhesion Kinase 1 | 2 | 2005 | 120 | 0.120 |
Why?
|
Pulmonary Artery | 1 | 2003 | 1946 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2004 | 2846 | 0.120 |
Why?
|
Rectal Neoplasms | 1 | 2023 | 1183 | 0.110 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 319 | 0.110 |
Why?
|
Massachusetts | 4 | 2016 | 8893 | 0.110 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 2 | 2005 | 183 | 0.110 |
Why?
|
Pleura | 2 | 2006 | 245 | 0.110 |
Why?
|
Endoscopy | 3 | 2001 | 1854 | 0.110 |
Why?
|
Deoxycytidine | 1 | 2018 | 887 | 0.110 |
Why?
|
Fundoplication | 2 | 2006 | 145 | 0.110 |
Why?
|
Feasibility Studies | 6 | 2013 | 5314 | 0.100 |
Why?
|
Thoracostomy | 1 | 2013 | 79 | 0.100 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2015 | 174 | 0.100 |
Why?
|
Antigens, Differentiation | 2 | 2008 | 921 | 0.100 |
Why?
|
Cefazolin | 1 | 2013 | 94 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2016 | 563 | 0.100 |
Why?
|
Neoplasm Proteins | 1 | 2004 | 3601 | 0.100 |
Why?
|
Catheter Ablation | 4 | 2008 | 2787 | 0.100 |
Why?
|
Military Personnel | 1 | 2021 | 1261 | 0.100 |
Why?
|
Remission Induction | 1 | 2018 | 2409 | 0.100 |
Why?
|
Community Health Services | 1 | 2017 | 659 | 0.100 |
Why?
|
Radiotherapy Dosage | 3 | 2021 | 2916 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2008 | 892 | 0.100 |
Why?
|
Comorbidity | 3 | 2012 | 10590 | 0.100 |
Why?
|
Population Surveillance | 2 | 2012 | 2594 | 0.100 |
Why?
|
Coronary Artery Bypass | 2 | 2016 | 2191 | 0.090 |
Why?
|
Cancer Vaccines | 3 | 2003 | 1041 | 0.090 |
Why?
|
Patient Advocacy | 1 | 2013 | 362 | 0.090 |
Why?
|
Cell Adhesion | 3 | 2005 | 3096 | 0.090 |
Why?
|
Prospective Studies | 15 | 2023 | 54921 | 0.090 |
Why?
|
Safety | 5 | 2010 | 1159 | 0.090 |
Why?
|
Immunotherapy | 2 | 2023 | 4748 | 0.090 |
Why?
|
Mediastinal Emphysema | 1 | 2010 | 29 | 0.090 |
Why?
|
Melanoma | 5 | 2011 | 5706 | 0.090 |
Why?
|
Sarcoma | 2 | 2017 | 1804 | 0.090 |
Why?
|
Dilatation | 2 | 2010 | 311 | 0.090 |
Why?
|
Unnecessary Procedures | 1 | 2013 | 412 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1323 | 0.090 |
Why?
|
Hypertension, Pulmonary | 1 | 2001 | 1605 | 0.090 |
Why?
|
United States | 14 | 2022 | 73033 | 0.090 |
Why?
|
Transduction, Genetic | 1 | 1993 | 899 | 0.080 |
Why?
|
Electrolysis | 1 | 2009 | 8 | 0.080 |
Why?
|
Radioactive Pollutants | 1 | 2009 | 13 | 0.080 |
Why?
|
Antibiotic Prophylaxis | 2 | 2013 | 640 | 0.080 |
Why?
|
Hydrostatic Pressure | 1 | 2009 | 98 | 0.080 |
Why?
|
Amifostine | 1 | 2009 | 39 | 0.080 |
Why?
|
Postoperative Care | 3 | 2013 | 1480 | 0.080 |
Why?
|
Aircraft | 1 | 2010 | 135 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.080 |
Why?
|
Awareness | 1 | 2013 | 653 | 0.080 |
Why?
|
Cyclosporins | 1 | 1989 | 216 | 0.080 |
Why?
|
Technology, Radiologic | 1 | 2009 | 160 | 0.080 |
Why?
|
Tritium | 1 | 2009 | 707 | 0.080 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 87 | 0.080 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2013 | 736 | 0.080 |
Why?
|
Heart-Lung Transplantation | 1 | 2009 | 87 | 0.080 |
Why?
|
Collateral Circulation | 3 | 1994 | 291 | 0.080 |
Why?
|
Cell Line, Tumor | 4 | 2006 | 17128 | 0.080 |
Why?
|
Proportional Hazards Models | 6 | 2021 | 12536 | 0.080 |
Why?
|
Cytoprotection | 1 | 2009 | 199 | 0.080 |
Why?
|
Radiography | 3 | 2013 | 6981 | 0.070 |
Why?
|
Quality of Health Care | 1 | 2023 | 4310 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 9614 | 0.070 |
Why?
|
Young Adult | 8 | 2020 | 60050 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2016 | 4857 | 0.070 |
Why?
|
Adolescent | 9 | 2024 | 89154 | 0.070 |
Why?
|
Azathioprine | 1 | 1989 | 354 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 1000 | 0.070 |
Why?
|
Barium | 1 | 2007 | 62 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2020 | 329 | 0.070 |
Why?
|
Europe | 2 | 2012 | 3438 | 0.070 |
Why?
|
Tissue Plasminogen Activator | 1 | 1993 | 1165 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5536 | 0.070 |
Why?
|
Pulmonary Circulation | 1 | 2009 | 745 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1883 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2783 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2599 | 0.070 |
Why?
|
Primary Prevention | 1 | 2013 | 1188 | 0.060 |
Why?
|
General Surgery | 2 | 2016 | 1721 | 0.060 |
Why?
|
Surgical Wound Infection | 2 | 2013 | 1546 | 0.060 |
Why?
|
Cohort Studies | 11 | 2023 | 41753 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3433 | 0.060 |
Why?
|
Total Quality Management | 1 | 2007 | 266 | 0.060 |
Why?
|
Immunization, Passive | 1 | 2008 | 619 | 0.060 |
Why?
|
Cytochalasin D | 1 | 2005 | 91 | 0.060 |
Why?
|
Gelsolin | 1 | 2006 | 189 | 0.060 |
Why?
|
Diagnostic Imaging | 2 | 2013 | 3533 | 0.060 |
Why?
|
Vinblastine | 1 | 2006 | 487 | 0.060 |
Why?
|
Nursing Homes | 1 | 2013 | 1084 | 0.060 |
Why?
|
Respiratory Function Tests | 3 | 2006 | 1695 | 0.060 |
Why?
|
Reoperation | 4 | 2009 | 4329 | 0.060 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 3726 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Vanadates | 1 | 2004 | 82 | 0.060 |
Why?
|
Culture Media, Serum-Free | 1 | 2004 | 148 | 0.060 |
Why?
|
Genistein | 1 | 2004 | 87 | 0.060 |
Why?
|
Incidental Findings | 1 | 2009 | 698 | 0.060 |
Why?
|
Cell Division | 4 | 2004 | 4473 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2011 | 1378 | 0.060 |
Why?
|
Cell Survival | 2 | 2006 | 5772 | 0.060 |
Why?
|
Naphthalenes | 1 | 2005 | 198 | 0.060 |
Why?
|
Cardiopulmonary Bypass | 1 | 2009 | 1097 | 0.060 |
Why?
|
Prednisone | 1 | 1989 | 1567 | 0.060 |
Why?
|
Microscopy, Video | 1 | 2004 | 241 | 0.060 |
Why?
|
Cyclin D1 | 1 | 2006 | 453 | 0.060 |
Why?
|
Travel | 1 | 2010 | 805 | 0.060 |
Why?
|
Pseudopodia | 1 | 2004 | 167 | 0.060 |
Why?
|
Transplantation, Homologous | 2 | 2009 | 4838 | 0.060 |
Why?
|
Video-Assisted Surgery | 1 | 2004 | 51 | 0.060 |
Why?
|
Indocyanine Green | 2 | 2017 | 237 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2013 | 2429 | 0.050 |
Why?
|
Phosphorylation | 2 | 2005 | 8314 | 0.050 |
Why?
|
Carcinoma | 2 | 2008 | 2330 | 0.050 |
Why?
|
Coronary Circulation | 3 | 1994 | 1617 | 0.050 |
Why?
|
Stents | 2 | 2007 | 3195 | 0.050 |
Why?
|
Disabled Persons | 1 | 2013 | 1210 | 0.050 |
Why?
|
Constriction, Pathologic | 2 | 2023 | 1104 | 0.050 |
Why?
|
Gastroscopy | 1 | 2004 | 213 | 0.050 |
Why?
|
Antigens, CD | 3 | 2011 | 4035 | 0.050 |
Why?
|
Head and Neck Neoplasms | 2 | 2010 | 2931 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2007 | 1622 | 0.050 |
Why?
|
Heart Function Tests | 1 | 2003 | 317 | 0.050 |
Why?
|
Video Recording | 3 | 1998 | 976 | 0.050 |
Why?
|
Fibroblast Growth Factor 1 | 2 | 1993 | 53 | 0.050 |
Why?
|
Antibodies, Blocking | 1 | 2003 | 250 | 0.050 |
Why?
|
Sex Distribution | 2 | 2005 | 2276 | 0.050 |
Why?
|
Esophagogastric Junction | 2 | 2016 | 350 | 0.050 |
Why?
|
Cell Size | 1 | 2004 | 626 | 0.050 |
Why?
|
Nomograms | 1 | 2024 | 236 | 0.050 |
Why?
|
Gastrostomy | 2 | 2001 | 325 | 0.050 |
Why?
|
Protein Subunits | 1 | 2005 | 943 | 0.050 |
Why?
|
Boston | 4 | 2020 | 9368 | 0.050 |
Why?
|
Age Distribution | 2 | 2005 | 2871 | 0.050 |
Why?
|
Vital Signs | 1 | 2023 | 145 | 0.050 |
Why?
|
Signal Transduction | 1 | 2005 | 23640 | 0.050 |
Why?
|
Forced Expiratory Volume | 2 | 2005 | 1831 | 0.050 |
Why?
|
United States Department of Veterans Affairs | 1 | 2007 | 937 | 0.050 |
Why?
|
Bronchoscopy | 2 | 2005 | 913 | 0.050 |
Why?
|
Endothelium, Vascular | 2 | 1994 | 4427 | 0.050 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2002 | 256 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5335 | 0.050 |
Why?
|
Respiratory Mechanics | 1 | 2005 | 721 | 0.050 |
Why?
|
Cell Movement | 3 | 2011 | 5209 | 0.050 |
Why?
|
Tracheal Diseases | 1 | 2002 | 118 | 0.050 |
Why?
|
Camptothecin | 2 | 2016 | 599 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2016 | 3415 | 0.050 |
Why?
|
Bronchial Diseases | 1 | 2002 | 151 | 0.050 |
Why?
|
Waiting Lists | 1 | 2006 | 779 | 0.050 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2006 | 777 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2007 | 12075 | 0.050 |
Why?
|
Tyrosine | 1 | 2005 | 1427 | 0.040 |
Why?
|
Respiratory Insufficiency | 1 | 2009 | 1240 | 0.040 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 1207 | 0.040 |
Why?
|
Protein Kinase C | 1 | 2005 | 1207 | 0.040 |
Why?
|
Clinical Competence | 1 | 2016 | 4857 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2005 | 1244 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3701 | 0.040 |
Why?
|
Edrophonium | 1 | 1999 | 4 | 0.040 |
Why?
|
Parasympathomimetics | 1 | 1999 | 28 | 0.040 |
Why?
|
Pyridostigmine Bromide | 1 | 1999 | 32 | 0.040 |
Why?
|
Cytoskeleton | 1 | 2005 | 1179 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2005 | 6225 | 0.040 |
Why?
|
Cystic Fibrosis | 1 | 2009 | 1294 | 0.040 |
Why?
|
Radiology | 1 | 2013 | 2104 | 0.040 |
Why?
|
Pulmonary Emphysema | 1 | 2005 | 689 | 0.040 |
Why?
|
Geriatrics | 2 | 2020 | 394 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2011 | 4648 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2004 | 904 | 0.040 |
Why?
|
Enzyme Activation | 1 | 2005 | 3587 | 0.040 |
Why?
|
Laryngoscopy | 1 | 2004 | 714 | 0.040 |
Why?
|
Probability | 1 | 2004 | 2479 | 0.040 |
Why?
|
Equipment Design | 1 | 2007 | 3522 | 0.040 |
Why?
|
Heredity | 1 | 2019 | 149 | 0.040 |
Why?
|
Polypharmacy | 1 | 2021 | 307 | 0.040 |
Why?
|
Ovarian Neoplasms | 2 | 2008 | 4915 | 0.040 |
Why?
|
Gynecomastia | 1 | 1999 | 88 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6517 | 0.040 |
Why?
|
Hospitals, Community | 1 | 2021 | 364 | 0.040 |
Why?
|
Receptors, Cholinergic | 1 | 1999 | 243 | 0.040 |
Why?
|
Colectomy | 1 | 2023 | 696 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 791 | 0.040 |
Why?
|
Cell Cycle | 1 | 2006 | 2932 | 0.040 |
Why?
|
Barrett Esophagus | 1 | 2001 | 495 | 0.040 |
Why?
|
Databases, Factual | 3 | 2024 | 8082 | 0.040 |
Why?
|
Fluorescent Dyes | 2 | 2017 | 1929 | 0.040 |
Why?
|
Gait | 1 | 2023 | 823 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 639 | 0.040 |
Why?
|
Sternoclavicular Joint | 1 | 1997 | 32 | 0.040 |
Why?
|
Africa | 1 | 2019 | 725 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2003 | 9536 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2022 | 974 | 0.030 |
Why?
|
Pericardial Window Techniques | 1 | 1996 | 10 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2016 | 6569 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 939 | 0.030 |
Why?
|
Hospitals, Military | 1 | 2016 | 62 | 0.030 |
Why?
|
Antibodies, Monoclonal | 3 | 2011 | 9253 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2004 | 1966 | 0.030 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2001 | 498 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 153 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1014 | 0.030 |
Why?
|
Menopause | 1 | 2003 | 1656 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2022 | 1273 | 0.030 |
Why?
|
Histones | 1 | 2006 | 2600 | 0.030 |
Why?
|
Reproducibility of Results | 5 | 2017 | 20218 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 1932 | 0.030 |
Why?
|
Hospitals, Public | 1 | 2016 | 204 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2003 | 975 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2016 | 5349 | 0.030 |
Why?
|
Maximum Tolerated Dose | 2 | 2009 | 897 | 0.030 |
Why?
|
Fibroblasts | 1 | 2005 | 4176 | 0.030 |
Why?
|
Surgical Flaps | 1 | 2023 | 1680 | 0.030 |
Why?
|
Heparin | 2 | 2020 | 1636 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2007 | 3488 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7469 | 0.030 |
Why?
|
Photochemotherapy | 1 | 2001 | 830 | 0.030 |
Why?
|
Immunohistochemistry | 3 | 2004 | 11068 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2002 | 1359 | 0.030 |
Why?
|
Inservice Training | 1 | 2016 | 375 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 1989 | 4271 | 0.030 |
Why?
|
Paclitaxel | 1 | 2021 | 1728 | 0.030 |
Why?
|
Anilides | 1 | 2016 | 413 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 2015 | 1130 | 0.030 |
Why?
|
Myocardial Ischemia | 2 | 1994 | 2138 | 0.030 |
Why?
|
Nausea | 1 | 2016 | 682 | 0.030 |
Why?
|
Heart Diseases | 2 | 2007 | 2819 | 0.030 |
Why?
|
Models, Biological | 2 | 2010 | 9493 | 0.030 |
Why?
|
Hospitalization | 1 | 2013 | 10843 | 0.030 |
Why?
|
Recovery of Function | 1 | 2023 | 2981 | 0.030 |
Why?
|
Coronary Disease | 3 | 1999 | 5919 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2011 | 5182 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9667 | 0.030 |
Why?
|
Graft Rejection | 2 | 2000 | 4500 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 1994 | 590 | 0.020 |
Why?
|
Cell Line | 1 | 2006 | 15597 | 0.020 |
Why?
|
Mutation | 1 | 2016 | 30214 | 0.020 |
Why?
|
Endothelial Growth Factors | 1 | 1994 | 671 | 0.020 |
Why?
|
Sex Factors | 2 | 2019 | 10629 | 0.020 |
Why?
|
Bronchiolitis Obliterans | 2 | 2006 | 221 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2011 | 62 | 0.020 |
Why?
|
Pedigree | 1 | 2019 | 4540 | 0.020 |
Why?
|
Laminin | 1 | 1993 | 405 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15944 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2003 | 4576 | 0.020 |
Why?
|
Lymphokines | 1 | 1994 | 924 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2016 | 2923 | 0.020 |
Why?
|
Fluorescence | 1 | 2013 | 757 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2697 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8750 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3210 | 0.020 |
Why?
|
Interleukin-15 | 1 | 2011 | 186 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 640 | 0.020 |
Why?
|
Retroviridae | 1 | 1993 | 846 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2003 | 8637 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3437 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 22286 | 0.020 |
Why?
|
Patient Readmission | 1 | 2024 | 3289 | 0.020 |
Why?
|
Apoptosis | 1 | 2006 | 9521 | 0.020 |
Why?
|
Water Pollutants, Radioactive | 1 | 2009 | 2 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2003 | 4904 | 0.020 |
Why?
|
Proteoglycans | 1 | 1993 | 809 | 0.020 |
Why?
|
Propensity Score | 1 | 2017 | 1970 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2005 | 10471 | 0.020 |
Why?
|
Scintillation Counting | 1 | 2009 | 36 | 0.020 |
Why?
|
Aerospace Medicine | 1 | 2010 | 95 | 0.020 |
Why?
|
Treatment Failure | 2 | 2006 | 2660 | 0.020 |
Why?
|
Fluoroscopy | 2 | 2005 | 948 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 2 | 1994 | 1495 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3814 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2011 | 828 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4030 | 0.020 |
Why?
|
Dogs | 4 | 1994 | 3843 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 2009 | 297 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1825 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 7851 | 0.020 |
Why?
|
Recurrence | 2 | 2003 | 8507 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2009 | 512 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 10396 | 0.020 |
Why?
|
Coronary Angiography | 1 | 1999 | 4541 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 960 | 0.020 |
Why?
|
Blotting, Southern | 2 | 2002 | 775 | 0.020 |
Why?
|
Proteins | 1 | 2002 | 6009 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5100 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1989 | 717 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6338 | 0.020 |
Why?
|
Cattle | 1 | 1993 | 3816 | 0.020 |
Why?
|
Digital Rectal Examination | 1 | 2007 | 42 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6668 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2914 | 0.020 |
Why?
|
Catheterization | 1 | 1992 | 1430 | 0.020 |
Why?
|
Drug Combinations | 1 | 1993 | 2088 | 0.020 |
Why?
|
Fee-for-Service Plans | 1 | 2011 | 713 | 0.020 |
Why?
|
Arteries | 1 | 1991 | 1127 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1326 | 0.020 |
Why?
|
Medically Uninsured | 1 | 2011 | 840 | 0.020 |
Why?
|
Papain | 1 | 2005 | 66 | 0.020 |
Why?
|
Palliative Care | 1 | 2020 | 3642 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2003 | 3798 | 0.010 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 14718 | 0.010 |
Why?
|
Pyridines | 1 | 2016 | 2893 | 0.010 |
Why?
|
Epitopes | 1 | 2011 | 2526 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 2002 | 6119 | 0.010 |
Why?
|
Cadaver | 1 | 1989 | 1361 | 0.010 |
Why?
|
Collagen | 1 | 1993 | 2641 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1895 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11101 | 0.010 |
Why?
|
Age of Onset | 1 | 2011 | 3347 | 0.010 |
Why?
|
Demography | 1 | 2009 | 1641 | 0.010 |
Why?
|
Hemangioendothelioma | 1 | 2004 | 112 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4854 | 0.010 |
Why?
|
Aorta | 1 | 1992 | 2045 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4063 | 0.010 |
Why?
|
Transfection | 1 | 1992 | 5757 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1801 | 0.010 |
Why?
|
Phenotype | 2 | 2011 | 16723 | 0.010 |
Why?
|
Kidney | 2 | 2009 | 7067 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 134 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2005 | 9116 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1542 | 0.010 |
Why?
|
Water | 1 | 2009 | 1421 | 0.010 |
Why?
|
Hot Temperature | 1 | 2009 | 1442 | 0.010 |
Why?
|
Animals | 11 | 2005 | 169225 | 0.010 |
Why?
|
Coronary Vessels | 1 | 1994 | 3125 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13289 | 0.010 |
Why?
|
Sheep | 1 | 2005 | 1449 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1481 | 0.010 |
Why?
|
Health Policy | 1 | 2015 | 2698 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 2003 | 491 | 0.010 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 57 | 0.010 |
Why?
|
Genetic Vectors | 1 | 1992 | 3402 | 0.010 |
Why?
|
Myocardium | 2 | 1994 | 4788 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2011 | 2324 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 2006 | 506 | 0.010 |
Why?
|
Thorax | 1 | 2005 | 557 | 0.010 |
Why?
|
Jejunostomy | 1 | 2001 | 61 | 0.010 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2002 | 200 | 0.010 |
Why?
|
Esophageal Fistula | 1 | 2001 | 60 | 0.010 |
Why?
|
North America | 1 | 2004 | 1289 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2001 | 26418 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 2006 | 846 | 0.010 |
Why?
|
Reference Values | 2 | 2002 | 4938 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 748 | 0.010 |
Why?
|
Electric Impedance | 1 | 2005 | 795 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2005 | 18345 | 0.010 |
Why?
|
Thromboembolism | 1 | 2007 | 1003 | 0.010 |
Why?
|
COS Cells | 1 | 2002 | 1135 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 1126 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5694 | 0.010 |
Why?
|
Health Surveys | 1 | 2010 | 4056 | 0.010 |
Why?
|
Galactorrhea | 1 | 1999 | 23 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2854 | 0.010 |
Why?
|
Premenopause | 1 | 2003 | 1039 | 0.010 |
Why?
|
Adenoviridae | 1 | 2003 | 1092 | 0.010 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 1999 | 83 | 0.010 |
Why?
|
Infant | 1 | 2001 | 36533 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 2002 | 403 | 0.010 |
Why?
|
History, 20th Century | 1 | 2007 | 2765 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2013 | 12464 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1989 | 6314 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 1616 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 36743 | 0.010 |
Why?
|
Cause of Death | 1 | 2009 | 3720 | 0.010 |
Why?
|
Models, Animal | 1 | 2005 | 2121 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2002 | 1892 | 0.010 |
Why?
|
Child, Preschool | 1 | 2001 | 42665 | 0.010 |
Why?
|
Medicaid | 1 | 2011 | 2840 | 0.010 |
Why?
|
Graft Survival | 1 | 1989 | 3894 | 0.010 |
Why?
|
Databases as Topic | 1 | 1999 | 472 | 0.010 |
Why?
|
Sternum | 1 | 1998 | 177 | 0.010 |
Why?
|
Genetic Engineering | 1 | 2003 | 935 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2003 | 1251 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18069 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1993 | 19015 | 0.010 |
Why?
|
China | 1 | 2003 | 2395 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2003 | 617 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2007 | 2101 | 0.010 |
Why?
|
Abdomen | 1 | 2001 | 1137 | 0.010 |
Why?
|
Karnofsky Performance Status | 1 | 1995 | 162 | 0.010 |
Why?
|
Rabbits | 2 | 1992 | 4771 | 0.010 |
Why?
|
Swine | 1 | 2005 | 6002 | 0.010 |
Why?
|
Chromonar | 1 | 1994 | 4 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2008 | 3116 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 2002 | 1383 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1999 | 735 | 0.010 |
Why?
|
Disease Management | 1 | 2004 | 2533 | 0.010 |
Why?
|
Neovascularization, Pathologic | 2 | 1994 | 2630 | 0.010 |
Why?
|
Medicare | 1 | 2011 | 6814 | 0.010 |
Why?
|
Cytomegalovirus Infections | 1 | 2000 | 836 | 0.010 |
Why?
|
Infusions, Intra-Arterial | 1 | 1993 | 221 | 0.010 |
Why?
|
Child | 1 | 2001 | 80905 | 0.010 |
Why?
|
Drainage | 1 | 1998 | 1183 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1994 | 748 | 0.010 |
Why?
|
Mitochondrial Swelling | 1 | 1991 | 15 | 0.010 |
Why?
|
Cineangiography | 1 | 1991 | 108 | 0.010 |
Why?
|
Risk | 1 | 2003 | 9609 | 0.010 |
Why?
|
Ear | 1 | 1991 | 172 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 1992 | 574 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3251 | 0.010 |
Why?
|
Virion | 1 | 1992 | 428 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1993 | 1498 | 0.010 |
Why?
|
Models, Statistical | 1 | 2003 | 5109 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 2002 | 7613 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2009 | 26377 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2002 | 12797 | 0.000 |
Why?
|
Arteriosclerosis | 1 | 1991 | 1055 | 0.000 |
Why?
|
Cytoplasm | 1 | 1991 | 1505 | 0.000 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4210 | 0.000 |
Why?
|
Disease Progression | 1 | 2003 | 13667 | 0.000 |
Why?
|
Endoplasmic Reticulum | 1 | 1991 | 1133 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 13000 | 0.000 |
Why?
|
Hemodynamics | 1 | 1994 | 4194 | 0.000 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 1994 | 3514 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1992 | 6070 | 0.000 |
Why?
|
Pilot Projects | 1 | 1995 | 8740 | 0.000 |
Why?
|
Heart | 1 | 1991 | 4445 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2003 | 21209 | 0.000 |
Why?
|
Mice | 1 | 2003 | 82024 | 0.000 |
Why?
|